Email this article 
Russian Federal clinical recomendations on chronic urticaria diagnostics and treatment
- Authors: Danilycheva IV1, Ilina NI1, Luss LV1, Fedenko ES1, Shulzhenko AE1
-
Affiliations:
- Institute of Immunology
- Issue: Vol 13, No 1 (2016)
- Pages: 38-46
- Section: Articles
- Submitted: 10.03.2020
- Published: 15.12.2016
- URL: https://rusalljournal.ru/raj/article/view/380
- DOI: https://doi.org/10.36691/RJA380
- ID: 380
Cite item
Open Access
Access granted
Abstract
The revised recomendations on chronic urticaria diagnostics and treatment created by leading Russian experts are presented.
Full Text
About the authors
I V Danilycheva
Institute of Immunology
Email: ivdanilycheva@mail.ru
N I Ilina
Institute of Immunology
L V Luss
Institute of Immunology
E S Fedenko
Institute of Immunology
A E Shulzhenko
Institute of Immunology
References
- Хаитов Р.М., Ильина Н.И. Аллергология и иммунология. Национальное руководство. М., «ГЭОТАР-Медиа», 2009, с. 75-98, 461-472.
- Аллергология. Федеральные клинические рекомендации. Главные редакторы: акад. РАН Р.М. Хаитов, проф. Н.И. Ильина. М. «Фармарус Принт Медиа». 2014, 126 с.
- Р.Н. Голубчикова, И.В. Данилычева. Хроническая идиопатическая крапивница. Диагностическая проблема. Рос. Аллергол. Журн. 2012, № 3, с. 3-6.
- Zuberbier T., Aberer W., Asero R. et al. EAACI.GA2LEN/EDF/ WAO urticaria guideline for the definition, classification, diagnosis, and management of urticaria: the 2013 revision and update. Allergy. 2014, v. 69, p.868-887.
- Saini S.S. Chronic Spontaneous Urticaria: Etiology and Pathogenesis. Immunol. Allergy Clin North Am 2014, v. 34, р. 33-52.
- Makris M., Maurer M. Zuberbier T. Pharmacotherapy of chronic spontaneous urticaria. Expert Opin. Pharmacother. 2013, v. 14, p. 2511-2519.
- Maurer M., Magerl M., Metz M., Zuberbier T. Revisions to the international guidelines on the diagnosis and therapy of chronic urticaria. J. Dtsch. Dermatol Ges. 2013, v. 11, p. 971-978.
- Maurer M., Rosen K.E., Hsieh H.J. et al. Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria. N. Engl. J. Med. 2013, v. 368, p. 924-35.
- Maurer M., Weller K., Bindslev-Jensen C. et al. Unmet clinical needs in chronic spontaneous urticaria. GA2LEN task forse report. Allergy. 2011, v. 66, p. 317-330.
- Kozel M.M., Mekkes J.R., Bossuyt P.M., Bos J.D. The effectiveness of a history-based diagnostic approach in chronic urticaria and angioedema Arch. Dermatol. 1998, v. 134, p. 1575-1580.
- Buss Y.A. et all. Chronic urticaria - wich clinical parameters are pathogenetically relevant? A retrospective investigation of 339 patientsJDDG, 2007, v. 1, p. 22-27
- S. J. Deacock. An approach to the patient with urticaria. Br. Society for Immunollogy, Clinical and Exeperimental Immunology. 2008, v. 153, p.151-161
- M. Goldenberg. Pharmaceutical Approval Update. P&T®. June 2014, v. 39 (6), p. 415-416.
- Martin Metz, Tatevik Ohanyan, Martin K. Church. et al. Omalizumab is an effective and rapidly acting therapy in difficult-to-treat chronic urticaria: A retrospective clinical analysis. Journal of Dermatological Science. 2014,v. 73, p. 57-62
- Namazy J., Cabana M.D., Scheuerle A. et al. The Xolair Pregnancy Registry (EXPECT): The safety of omalizumab use during pregnancy. J.Allergy Clin. Immunol. 2015, v. 135, р. 407-412.
Supplementary files
